6-Pyruvoyltetrahydropterin synthase deficiency

A rare metabolic disorder affecting neurotransmitter synthesis

6-Pyruvoyltetrahydropterin synthase deficiency
Synonyms	PTPS deficiency
Pronounce	N/A
Specialty	N/A
Symptoms	Hyperphenylalaninemia, neurological dysfunction, developmental delay
Complications	Intellectual disability, seizures
Onset	Infancy
Duration	Lifelong
Types	N/A
Causes	Mutations in the PTS gene
Risks	Family history
Diagnosis	Genetic testing, newborn screening
Differential diagnosis	Phenylketonuria, Dihydropteridine reductase deficiency
Prevention	N/A
Treatment	Dietary management, tetrahydrobiopterin supplementation
Medication	Sapropterin
Prognosis	Variable, depends on early diagnosis and treatment
Frequency	Rare
Deaths	N/A

Autosomal recessive

6-Pyruvoyltetrahydropterin synthase deficiency (PTPS deficiency) is a rare metabolic disorder that affects the synthesis of tetrahydrobiopterin (BH4), a critical cofactor in the production of several important neurotransmitters. This condition is part of a group of disorders known as hyperphenylalaninemia due to its effect on phenylalanine metabolism.

Pathophysiology

6-Pyruvoyltetrahydropterin synthase (PTPS) is an enzyme involved in the biosynthesis of tetrahydrobiopterin (BH4) from guanosine triphosphate (GTP). BH4 is an essential cofactor for the hydroxylation of phenylalanine, tyrosine, and tryptophan, which are precursors to the neurotransmitters dopamine, norepinephrine, epinephrine, and serotonin.

In PTPS deficiency, mutations in the PTS gene lead to reduced or absent activity of the PTPS enzyme. This results in decreased levels of BH4, leading to impaired hydroxylation of phenylalanine and accumulation of phenylalanine in the blood. Additionally, the synthesis of neurotransmitters is disrupted, leading to neurological symptoms.

Clinical Presentation

The clinical manifestations of PTPS deficiency can vary widely, but they often include:

• Hyperphenylalaninemia: Elevated levels of phenylalanine in the blood, which can lead to intellectual disability if untreated.
• Neurological symptoms: These may include developmental delay, hypotonia, seizures, and movement disorders.
• Behavioral issues: Such as irritability, sleep disturbances, and autistic-like behaviors.

Diagnosis

Diagnosis of PTPS deficiency involves a combination of clinical evaluation, biochemical testing, and genetic analysis. Key diagnostic steps include:

• Measurement of phenylalanine levels in the blood.
• Analysis of biopterin and neopterin levels in urine or blood to assess BH4 metabolism.
• Genetic testing to identify mutations in the PTS gene.

Treatment

Management of PTPS deficiency focuses on reducing phenylalanine levels and supplementing neurotransmitter precursors. Treatment strategies include:

• A low-phenylalanine diet to prevent the accumulation of phenylalanine.
• BH4 supplementation to restore cofactor levels and improve neurotransmitter synthesis.
• Administration of neurotransmitter precursors such as L-DOPA and 5-hydroxytryptophan (5-HTP) to bypass the metabolic block.

Prognosis

With early diagnosis and appropriate treatment, individuals with PTPS deficiency can have improved outcomes. However, the degree of neurological impairment can vary, and some individuals may continue to experience developmental challenges.

Related Pages

• Tetrahydrobiopterin deficiency
• Phenylketonuria
• Metabolic disorder
• Neurotransmitter

This article is a stub related to genetics. You can help WikiMD by expanding it!